These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16885336)

  • 1. Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin.
    Yu YP; Luo JH
    Cancer Res; 2006 Aug; 66(15):7414-9. PubMed ID: 16885336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of myopodin expression reduces invasion and motility of PC-3 prostate cancer cells.
    De Ganck A; De Corte V; Bruyneel E; Bracke M; Vandekerckhove J; Gettemans J
    Int J Oncol; 2009 May; 34(5):1403-9. PubMed ID: 19360353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of myopodin expression associated with prostate cancer relapse.
    Yu YP; Tseng GC; Luo JH
    Urology; 2006 Sep; 68(3):578-82. PubMed ID: 16979744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myopodin isoforms alter the chemokinetic response of PC3 cells in response to different migration stimuli via differential effects on Rho-ROCK signaling pathways.
    Kai F; Tanner K; King C; Duncan R
    Carcinogenesis; 2012 Nov; 33(11):2100-7. PubMed ID: 22915763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylation and interaction of myopodin by integrin-link kinase lead to suppression of cell growth and motility in prostate cancer cells.
    Yu YP; Luo JH
    Oncogene; 2011 Dec; 30(49):4855-63. PubMed ID: 21643011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of myopodin induces suppression of tumor growth and metastasis.
    Jing L; Liu L; Yu YP; Dhir R; Acquafondada M; Landsittel D; Cieply K; Wells A; Luo JH
    Am J Pathol; 2004 May; 164(5):1799-806. PubMed ID: 15111326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sarcomeric Z-disc component myopodin is a multiadapter protein that interacts with filamin and alpha-actinin.
    Linnemann A; van der Ven PF; Vakeel P; Albinus B; Simonis D; Bendas G; Schenk JA; Micheel B; Kley RA; Fürst DO
    Eur J Cell Biol; 2010 Sep; 89(9):681-92. PubMed ID: 20554076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple isoforms of the tumor suppressor myopodin are simultaneously transcribed in cancer cells.
    De Ganck A; De Corte V; Staes A; Gevaert K; Vandekerckhove J; Gettemans J
    Biochem Biophys Res Commun; 2008 May; 370(2):269-73. PubMed ID: 18371299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome.
    Sanchez-Carbayo M; Schwarz K; Charytonowicz E; Cordon-Cardo C; Mundel P
    Oncogene; 2003 Aug; 22(34):5298-305. PubMed ID: 12917631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of myopodin methylation in bladder cancer.
    Cebrian V; Alvarez M; Aleman A; Palou J; Bellmunt J; Gonzalez-Peramato P; Cordón-Cardo C; García J; Piulats JM; Sánchez-Carbayo M
    J Pathol; 2008 Sep; 216(1):111-9. PubMed ID: 18636402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tes, a specific Mena interacting partner, breaks the rules for EVH1 binding.
    Boëda B; Briggs DC; Higgins T; Garvalov BK; Fadden AJ; McDonald NQ; Way M
    Mol Cell; 2007 Dec; 28(6):1071-82. PubMed ID: 18158903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.
    Darnel AD; Behmoaram E; Vollmer RT; Corcos J; Bijian K; Sircar K; Su J; Jiao J; Alaoui-Jamali MA; Bismar TA
    Clin Cancer Res; 2009 Feb; 15(4):1376-83. PubMed ID: 19228738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers.
    Lin F; Yu YP; Woods J; Cieply K; Gooding B; Finkelstein P; Dhir R; Krill D; Becich MJ; Michalopoulos G; Finkelstein S; Luo JH
    Am J Pathol; 2001 Nov; 159(5):1603-12. PubMed ID: 11696420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A zyxin head-tail interaction regulates zyxin-VASP complex formation.
    Moody JD; Grange J; Ascione MP; Boothe D; Bushnell E; Hansen MD
    Biochem Biophys Res Commun; 2009 Jan; 378(3):625-8. PubMed ID: 19061869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation- and stress-dependent nuclear cytoplasmic redistribution of myopodin, a novel actin-bundling protein.
    Weins A; Schwarz K; Faul C; Barisoni L; Linke WA; Mundel P
    J Cell Biol; 2001 Oct; 155(3):393-404. PubMed ID: 11673475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer cell migration induced by myopodin isoforms is associated with formation of morphologically and biochemically distinct actin networks.
    Kai F; Duncan R
    FASEB J; 2013 Dec; 27(12):5046-58. PubMed ID: 24005909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription.
    Torosyan Y; Dobi A; Naga S; Mezhevaya K; Glasman M; Norris C; Jiang G; Mueller G; Pollard H; Srivastava M
    Cancer Res; 2006 Oct; 66(19):9609-16. PubMed ID: 17018618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
    Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
    Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vimentin affects the mobility and invasiveness of prostate cancer cells.
    Zhao Y; Yan Q; Long X; Chen X; Wang Y
    Cell Biochem Funct; 2008; 26(5):571-7. PubMed ID: 18464297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts.
    Zhang J; Park SI; Artime MC; Summy JM; Shah AN; Bomser JA; Dorfleutner A; Flynn DC; Gallick GE
    J Clin Invest; 2007 Oct; 117(10):2962-73. PubMed ID: 17885682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.